Luspatercept (mIgG2a)

Luspatercept (mIgG2a) (RAP-536) is a fusion protein, consisting of a modified extracellular domain of human ActRIIB linked to the murine IgG2a Fc domain. Luspatercept (mIgG2a) inhibits Smad2/3 signaling, promotes differentiation of late-stage erythroid precursors and mitigates ineffective erythropoiesis (IE) in murine β-thalassemia. Luspatercept (mIgG2a) reduces anemia, α-globin aggregates, hemolysis, and disease complications of IE such as iron overload, splenomegaly, and bone defects[1].

Product Specifications

CAS Number

[1373715-00-4]

Product Name Alternative

RAP-536

UNSPSC

12352203

Target

TGF-beta/Smad

Related Pathways

Stem Cell/Wnt; TGF-beta/Smad

Field of Research

Metabolic Disease

Smiles

[Luspatercept(mIgG2a)]

References & Citations

[1]Suragani RN, et al. Modified activin receptor IIB ligand trap mitigates ineffective erythropoiesis and disease complications in murine β-thalassemia. Blood. 2014 Jun 19; 123 (25) :3864-72.